Pfizer and BMS team with Mark Cuban's Cost Plus Drug Co. to offer Eliquis at transparent cash prices, challenging pricing norms. Investors should weigh margin against reach as Pfizer faces projected earnings declines.Abstract: Pfizer and Bristol Myers Squibb have partnered with Mark Cuban's Cost Plus Drug Company to offer Eliquis at a transparent cash price, expanding access for patients paying out of pocket and potentially altering standard pricing and distribution dynamics in the pharmaceutical sector. The arrangement suggests a shift toward price transparency and new distribution models, with potential implications for margins, market reach, and overall affordability. For investors, the key questions are the trade-off between volume and margin, the endurance of cost advantages, and the forecasted earnings decline for Pfizer over the next three years, which could influence valuation and strategic responses.

NodeGuardian

2026-05-05 18:09:32

Abstract generation in progress

Pfizer and Bristol Myers Squibb are collaborating with Mark Cuban’s Cost Plus Drug Company to make Eliquis more accessible and transparently priced for cash-paying patients. This move, which comes as Pfizer’s shares trade at $27.0 with mixed returns over different timeframes, could impact perceptions of drug pricing, distribution models, and affordability within the pharmaceutical industry. Investors are advised to consider the potential trade-off between margin and reach, and monitor prescription volumes and Eliquis economics, especially given forecasts of declining earnings for Pfizer over the next three years.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
WCTCTradingKingPK
698.74K Popularity
#
USSeeksStrategicBitcoinReserve
58.86M Popularity
#
BitcoinETFOptionLimitQuadruples
1.08M Popularity
#
#FedHoldsRateButDividesDeepen
65.57K Popularity
#
DeFiLossesTop600MInApril
10.22M Popularity

Sitemap

Pfizer Eliquis Price Move With Cost Plus Raises Questions On Valuation

Trending Topics

WCTCTradingKingPK

USSeeksStrategicBitcoinReserve

BitcoinETFOptionLimitQuadruples

#FedHoldsRateButDividesDeepen

DeFiLossesTop600MInApril

Pin